Atlas FDA

ORSIRO Mission Sirolimus Eluting Coronary Stent System

FDA premarket approval P170030/S039 · decided 2024-06-06

Approval details

PMA number
P170030
Supplement
S039
Supplement type
Special (Immediate Track)
Supplement reason
Labeling Change - Indications/instructions/shelf life/tradename
Trade name
ORSIRO Mission Sirolimus Eluting Coronary Stent System
Generic name
Coronary drug-eluting stent
Applicant
Biotronik AG
Date received
2024-05-10
Decision date
2024-06-06
Days to decision
27 days
Decision code
APPR
Product code
NIQ
Advisory committee
Cardiovascular
Expedited review
No
Location
Bülach
Statement
Approval for a labeling change to include an additional drug interaction statement.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
PHERON PERIPHERAL PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY (PTA) CATHETER (K052757)Biotronik AG2005-10-28